Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members
- PMID: 9704930
- DOI: 10.1038/sj.onc.1201974
Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members
Abstract
p53 is a tumour suppressor gene which functions as a transcription factor to upregulate genes for growth arrest and apoptosis following DNA damage. p53 mutations are associated with Li-Fraumeni and Li-Fraumeni like syndromes. Recently mutations of the oligomerization domain have been isolated from an LFS and an LFL family affecting respectively codon 344 (Leu to Pro) and 337 (Arg to Cys). The present study was designed to determine the affect of these mutations on the function of p53 protein. p53 344 Leu to Pro existed only in a monomeric form and could not bind to DNA. It was inactive at inducing apoptosis, transactivating luciferase from a bax promoter and inhibiting cell growth. In contrast, p53 337 Arg to Cys could form tetramers and could bind to DNA. However, p53 337 Arg to Cys was not fully active and could only induce apoptosis, transactivate luciferase from a bax promoter and inhibit cell growth with approximately 60% of the ability of wild-type p53. Both mutant proteins had reduced ability to bind to MDM2, p53 337 Arg to Cys being more reduced than p53 344 Leu to Pro. These results indicate that point mutations in the oligomerization domain can disrupt p53 function. In addition, the value of LFS and LFL families for the further understanding of the biological and biochemical properties of p53 is demonstrated.
Similar articles
-
Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.Oncogene. 1998 Aug 6;17(5):651-6. doi: 10.1038/sj.onc.1202062. Oncogene. 1998. PMID: 9704931
-
Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.Cancer Res. 2001 Feb 15;61(4):1741-6. Cancer Res. 2001. PMID: 11245491
-
RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.Oncogene. 2002 May 2;21(19):2961-70. doi: 10.1038/sj.onc.1205372. Oncogene. 2002. PMID: 12082526
-
TP53, hChk2, and the Li-Fraumeni syndrome.Methods Mol Biol. 2003;222:117-29. doi: 10.1385/1-59259-328-3:117. Methods Mol Biol. 2003. PMID: 12710683 Review.
-
The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).Int J Oncol. 2014 Jun;44(6):1813-9. doi: 10.3892/ijo.2014.2377. Epub 2014 Apr 10. Int J Oncol. 2014. PMID: 24718924 Review.
Cited by
-
Cotranslational protein assembly imposes evolutionary constraints on homomeric proteins.Nat Struct Mol Biol. 2018 Mar;25(3):279-288. doi: 10.1038/s41594-018-0029-5. Epub 2018 Feb 12. Nat Struct Mol Biol. 2018. PMID: 29434345 Free PMC article.
-
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.Tumour Biol. 2013 Aug;34(4):2063-74. doi: 10.1007/s13277-013-0871-3. Epub 2013 Jun 5. Tumour Biol. 2013. PMID: 23737287 Review.
-
Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2.Mol Oncol. 2020 Jan;14(1):69-86. doi: 10.1002/1878-0261.12592. Epub 2019 Nov 15. Mol Oncol. 2020. PMID: 31665549 Free PMC article.
-
TP53-Associated Pediatric Malignancies.Genes Cancer. 2011 Apr;2(4):485-90. doi: 10.1177/1947601911409745. Genes Cancer. 2011. PMID: 21779516 Free PMC article.
-
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.Nat Rev Clin Oncol. 2018 Jan;15(1):13-30. doi: 10.1038/nrclinonc.2017.151. Epub 2017 Sep 26. Nat Rev Clin Oncol. 2018. PMID: 28948977 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous